One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1093/annonc/mdx362.009
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Sep 1, 2017 |
 License type: publisher-specific-oa |
Affiliation: Institut Jules Bordet, Novartis (Switzerland), Breast International Group, Sunnybrook Health Science Centre, National Institute of Oncology, National Cancer Institute, Sana Klinikum Offenbach, Johns Hopkins Medicine, Johns Hopkins University, University of Sydney, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Helios Hospital Berlin-Buch, Dana-Farber Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Instituto Nacional do Câncer, Frontier Agriculture (United Kingdom), Memorial Sloan Kettering Cancer Center, Mayo Clinic, Winneshiek Medical Center, Pontifícia Universidade Católica do Rio Grande do Sul
158PD - Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
